NCT00891904 · OUTCOME

Feasibility as Assessed According to Ability to Deliver the Entire Treatment Regimen to 80% of Patients

Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer · Source last updated 2016-04-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: 2 years

Analysis population: Trial terminated early. Too few patients to analyze.

Groups in this outcome

Biological/Vaccine: Cetuximab

All patients enrolled will receive cetuximab 400 mg/m 2 IV x 1 dose 1 week prior to delivery of SBRT. Patients will then receive 15 Gy x 1 using SBRT and cetuximab i.v. 250 mg/m2 weekly for 4 weeks (total of 5 doses at 250 mg/m2).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Biological/Vaccine: Cetuximab	0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

counts
group Id
OG000
value
0
units
Participants

groups

description
All patients enrolled will receive cetuximab 400 mg/m 2 IV x 1 dose 1 week prior to delivery of SBRT. Patients will then receive 15 Gy x 1 using SBRT and cetuximab i.v. 250 mg/m2 weekly for 4 weeks (total of 5 doses at 250 mg/m2).
id
OG000
title
Biological/Vaccine: Cetuximab

population Description

Trial terminated early. Too few patients to analyze.

reporting Status

POSTED

time Frame

2 years

title

Feasibility as Assessed According to Ability to Deliver the Entire Treatment Regimen to 80% of Patients

type

SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice